13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02511028 (ClinicalTrials.gov) | November 27, 2015 | 28/7/2015 | In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging | In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging | Multiple Sclerosis | Drug: Ferumoxytol | National Institute of Neurological Disorders and Stroke (NINDS) | National Institutes of Health Clinical Center (CC) | Completed | 18 Years | 70 Years | All | 14 | Phase 1 | United States |
| 2 | EUCTR2014-003145-99-GB (EUCTR) | 19/03/2015 | 19/01/2015 | A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis. | A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial - CCMR One | Relapsing-remitting multiple sclerosis already on interferon-beta therapy MedDRA version: 17.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Targretin Product Name: Bexarotene INN or Proposed INN: Bexarotene | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | United Kingdom | ||
| 3 | NCT02418325 (ClinicalTrials.gov) | February 2015 | 8/4/2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Genesis Limited | NULL | Terminated | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | Trinidad and Tobago |
| 4 | NCT02418351 (ClinicalTrials.gov) | February 2015 | 8/4/2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Genesis Limited | NULL | Terminated | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago |
| 5 | NCT02587806 (ClinicalTrials.gov) | February 2015 | 26/10/2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | NULL | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago |
| 6 | NCT02587715 (ClinicalTrials.gov) | February 2015 | 26/10/2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | NULL | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | Trinidad and Tobago |
| 7 | NCT02137044 (ClinicalTrials.gov) | July 2014 | 22/4/2014 | Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study | Improving the Quality of Care for Pain and Depression in Persons With Multiple Sclerosis | Multiple Sclerosis;Pain;Depression | Behavioral: Collaborative Care (CC) | University of Washington | Patient-Centered Outcomes Research Institute | Completed | 18 Years | N/A | All | 195 | N/A | United States |
| 8 | NCT01037088 (ClinicalTrials.gov) | December 2009 | 17/12/2009 | Effects of Vaporized Marijuana on Neuropathic Pain | CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain | Neuropathic Pain;Reflex Sympathetic Dystrophy;Peripheral Neuropathy;Post-herpetic Neuralgia;Spinal Cord Injury;Multiple Sclerosis | Drug: Mild dose cannabis;Drug: Low dose cannabis;Drug: Cannabis | University of California, Davis | Center for Medicinal Cannabis Research;VA Northern California Health Care System | Completed | 18 Years | 70 Years | All | 44 | Phase 1/Phase 2 | United States |
| 9 | EUCTR2005-000171-18-FI (EUCTR) | 12/05/2005 | 18/04/2005 | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses) | Product Name: Temsirolimus Tablets Product Code: CCI-779 INN or Proposed INN: Temsirolimus Other descriptive name: WAY-130799 | Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development | NULL | Not Recruiting | Female: yes Male: yes | 180 | Finland | |||
| 10 | NCT00228397 (ClinicalTrials.gov) | November 2003 | 16/9/2005 | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis | A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: CCI-779 | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Completed | N/A | N/A | Both | 221 | Phase 2 | NULL |